Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children with Recurrent Supratentorial Brain Tumors
We are using HSV G207 because it has been shown to be safe in Phase I trials in adults with brain tumors and some adults responded to the treatment. The goal of this study is to determine the highest safe dose (maximum tolerated dose) without causing severe side effects. We also want to learn what kind of side effects can be caused by G207 and what side effects can be caused by G207 when given in combination with a single dose of radiation therapy. G207 is an experimental herpes simplex virus (HSV). HSV causes cold sores and, rarely, causes a severe brain infection. G207 has been genetically changed and weakened, in the hope that only cancer cells will be infected and killed by the virus, without harming normal brain tissue. A dose of radiation combined with G207 may increase the virus’ ability to kill cancer cells. The purpose of this study is to test the human safety of G207 alone or combined with a single dose of radiation to see what effects (good or bad) it has on you and your brain tumor. It is our hope that G207 will be a safe and an effective treatment for childhood brain tumors.